Association between SARS-CoV-2 anti-spike antibody titers and the development of post-COVID conditions : A retrospective observational study
2023, National Center for Global Health and Medicine..
The symptoms that persist after an acute coronavirus disease 2019 (COVID-19) are referred to as post- COVID conditions. Although the cause of post-COVID conditions remains unclear, the host immune response to SARS-CoV-2 may be involved. Hence, we aimed to investigate the effect of serum antibody titers against SARS-CoV-2 on the development of post-COVID conditions. We conducted a retrospective observational study of COVID-19-recovered individuals who attended the clinic at the National Center for Global Health and Medicine between January 2020 and April 2021. Serum SARS-CoV-2 anti-spike antibody titers were measured and a questionnaire survey was used to collect information on the presence of post-COVID conditions and demographic characteristics of the participants. Participants were then divided into two groups: high peak antibody titer group [≥ 0.759 OD450 value], and low peak antibody titer group [< 0.759 OD450 value] and compared their frequency of post-COVID conditions. Of 526 individuals attending the clinic, 457 (86.9%) responded to the questionnaire. We analyzed the data of 227 (49.7%) participants with measurements of serum antibody titers during the peak period. The incidence of depressed mood was significantly higher in the group with higher antibody titers (odds ratio: 2.34, 95% CI: 1.17-4.67, p = 0.016). There was no significant difference in the frequency of the remaining symptoms between the two groups. Among post-COVID conditions, the depressed mood was more frequent in the group with high serum antibody titers which suggests a difference in pathogenesis between depressive mood and other post-COVID conditions that requires further investigation.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:5 |
|---|---|
| Enthalten in: |
Global health & medicine - 5(2023), 2 vom: 30. Apr., Seite 106-111 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Miyazato, Yusuke [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Antibody titer |
|---|
| Anmerkungen: |
Date Revised 03.05.2023 published: Print Citation Status PubMed-not-MEDLINE |
|---|
| doi: |
10.35772/ghm.2022.01070 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM356315681 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM356315681 | ||
| 003 | DE-627 | ||
| 005 | 20231226070212.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.35772/ghm.2022.01070 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1187.xml |
| 035 | |a (DE-627)NLM356315681 | ||
| 035 | |a (NLM)37128226 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Miyazato, Yusuke |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Association between SARS-CoV-2 anti-spike antibody titers and the development of post-COVID conditions |b A retrospective observational study |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 03.05.2023 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status PubMed-not-MEDLINE | ||
| 520 | |a 2023, National Center for Global Health and Medicine. | ||
| 520 | |a The symptoms that persist after an acute coronavirus disease 2019 (COVID-19) are referred to as post- COVID conditions. Although the cause of post-COVID conditions remains unclear, the host immune response to SARS-CoV-2 may be involved. Hence, we aimed to investigate the effect of serum antibody titers against SARS-CoV-2 on the development of post-COVID conditions. We conducted a retrospective observational study of COVID-19-recovered individuals who attended the clinic at the National Center for Global Health and Medicine between January 2020 and April 2021. Serum SARS-CoV-2 anti-spike antibody titers were measured and a questionnaire survey was used to collect information on the presence of post-COVID conditions and demographic characteristics of the participants. Participants were then divided into two groups: high peak antibody titer group [≥ 0.759 OD450 value], and low peak antibody titer group [< 0.759 OD450 value] and compared their frequency of post-COVID conditions. Of 526 individuals attending the clinic, 457 (86.9%) responded to the questionnaire. We analyzed the data of 227 (49.7%) participants with measurements of serum antibody titers during the peak period. The incidence of depressed mood was significantly higher in the group with higher antibody titers (odds ratio: 2.34, 95% CI: 1.17-4.67, p = 0.016). There was no significant difference in the frequency of the remaining symptoms between the two groups. Among post-COVID conditions, the depressed mood was more frequent in the group with high serum antibody titers which suggests a difference in pathogenesis between depressive mood and other post-COVID conditions that requires further investigation | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a COVID-19 | |
| 650 | 4 | |a SARS-CoV-2 | |
| 650 | 4 | |a antibody titer | |
| 650 | 4 | |a post-COVID condition | |
| 650 | 4 | |a questionnaire survey | |
| 700 | 1 | |a Tsuzuki, Shinya |e verfasserin |4 aut | |
| 700 | 1 | |a Matsunaga, Akihiro |e verfasserin |4 aut | |
| 700 | 1 | |a Morioka, Shinichiro |e verfasserin |4 aut | |
| 700 | 1 | |a Terada, Mari |e verfasserin |4 aut | |
| 700 | 1 | |a Saito, Sho |e verfasserin |4 aut | |
| 700 | 1 | |a Iwamoto, Noriko |e verfasserin |4 aut | |
| 700 | 1 | |a Kutsuna, Satoshi |e verfasserin |4 aut | |
| 700 | 1 | |a Ishizaka, Yukihito |e verfasserin |4 aut | |
| 700 | 1 | |a Ohmagari, Norio |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Global health & medicine |d 2019 |g 5(2023), 2 vom: 30. Apr., Seite 106-111 |w (DE-627)NLM318957922 |x 2434-9194 |7 nnns |
| 773 | 1 | 8 | |g volume:5 |g year:2023 |g number:2 |g day:30 |g month:04 |g pages:106-111 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.35772/ghm.2022.01070 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 5 |j 2023 |e 2 |b 30 |c 04 |h 106-111 | ||